ASESID: Semantic and Syntactic Computerized Analysis of Free Speech

Sponsor
University Hospital, Brest (Other)
Overall Status
Recruiting
CT.gov ID
NCT03525054
Collaborator
(none)
150
3
61.4
50
0.8

Study Details

Study Description

Brief Summary

Subtle speech disorganization could be predictive of a transition to schizophrenia of ultra-high-risk patients. The aim of our longitudinal multicenter cohort study is to identify specific linguistic markers of the psychotic transition to validate a french predictive model of this transition using computerized speech analysis techniques

Detailed Description

Different scales allow identification of patients at ultra-high-risk to develop psychosis. The current challenge is to identify a predictive marker of transition to schizophrenia. Language disorders, which reflect psyche, could be one of these markers. Computerized speech analysis techniques such as Latent Semantic Analysis (LSA) have already proven their reliability in schizophrenia. These techniques reveal subtle speech disorganization that would be predictive of a clinical transition of ultra-high-risk psychotic patients. A combination of semantic and syntactic analysis could accurately predict the psychotic transition. The aim of our longitudinal multicenter cohort study is to validate this predicitve model in french language as well as identifying specific linguistic markers of the psychotic transition.

The initial report including the CAARMS is completed with an audio recording from the initial medical interview. The recording will be transcribed and analyzed by computer following the method of lemmatization and vectorial analysis (LSA). An analysis of the grammatical function (number of words, rate of the various grammatical functions) will also be performed. This first analysis will emerge linguistic markers correlated to transition to psychosis that we will use to construct a predictive model for transition to schizophrenia.

Study Design

Study Type:
Observational
Anticipated Enrollment :
150 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Semantic and Syntactic Computerized Analysis of Free Speech
Actual Study Start Date :
May 18, 2018
Anticipated Primary Completion Date :
Jun 30, 2023
Anticipated Study Completion Date :
Jun 30, 2023

Outcome Measures

Primary Outcome Measures

  1. Transition to schizophrenia [2 years]

    Determined from the CAARMS scale (COMPREHENSIVE ASSESSMENT OF AT RISK MENTAL STATES)

Secondary Outcome Measures

  1. Identification of patients at "ultra high risk " for developing schizophrenia [Day 0]

    Determined from the CAARMS scale ( COMPREHENSIVE ASSESSMENT OF AT RISK MENTAL STATES)

Eligibility Criteria

Criteria

Ages Eligible for Study:
15 Years to 30 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Major and/or minor from 15 to 30 years old

  • Who alleged a suicidal gesture or idea or behavior that has repercussions in their emotional, social or professional life

  • Patient at risk 1, 2 or 3 according to the CAARMS score

  • If patients receive neuroleptic treatment that impairs cognitive abilities, a one-week wash-out period will be scheduled prior to assessment.

Exclusion Criteria:
  • History of psychosis

  • Risk of self-harm or violence not compatible with outpatient treatment

  • QI<70 (WAIS)

  • Neurological disorder or major health problem

  • Impossibility to interrupt neuroleptic treatment for one week

  • Refusal to participate

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHRU de Brest Brest France 29609
2 Meunier Sophie Caen France
3 CH de SAINT ANNE Paris France 750144

Sponsors and Collaborators

  • University Hospital, Brest

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Brest
ClinicalTrials.gov Identifier:
NCT03525054
Other Study ID Numbers:
  • ASESID (29BRC17.0198)
First Posted:
May 15, 2018
Last Update Posted:
Jun 6, 2022
Last Verified:
Jun 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Brest
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 6, 2022